Hims & Hers Health
What matters nowUpdated 6 h ago
- The latest development on record is an 8-K filed on Oct 7, 2026, reporting a director or officer change under Item 5.02 1.
- HIMS last traded at $29.99 (pooled 24/7 venue price), down 1.9% from the previous close of $30.58. The largest recent move was +10.15% on Oct 9 (z-score 2.92), followed by -5.07% on Oct 8; the closest filing in our records is the Oct 7 8-K 1.
- Q2 2026 (quarter ended Jun 30, reported Aug 10) revenue was $753.2M, up 38% from a year earlier ·. Trailing twelve-month revenue is $2.58B with a 68.4% gross margin, a -6.0% operating margin and a net loss of $142.0M. Rest of World revenue reached $131.4M in Q2, up from $7.5M a year earlier, helped by the Eucalyptus deal closing in June. Subscribers stood at 2.891 million at the end of Q2, up 19% year over year.
- Market capitalisation is $6.95B, or 2.7 times trailing sales. Over the last 180 days insiders sold 394,683 shares worth $12.0M in 26 sales, all 26 flagged as planned, against one purchase worth $1.2M, a net outflow of $10.8M.
- Next, Q3 2026 earnings are estimated for Nov 9, 2026, not yet confirmed. The September CPI print is due Oct 14 at 12:30 UTC, and Polymarket gives 81.5% odds of no Fed rate change after the October 2026 meeting, against 17.5% for a 25 bp increase.
Hims & Hers Health is a US consumer health platform that sells subscription care for sexual health, hair loss, dermatology, mental health, weight loss and hormone health under its Hims and Hers brands. In 2025 it added testosterone, menopause and comprehensive lab testing, bought the European platform Zava and, in June 2026, closed its Australian acquisition Eucalyptus.
How it makes money
Customers pay a recurring subscription for telehealth consultations, prescriptions and follow-up care delivered through licensed providers. Revenue therefore depends on the number of subscribers and revenue per subscriber, which reached $92 a month in Q2 2026. Gross margin fell to 64 percent in Q2 2026 from 76 percent a year earlier as the company moved its weight-loss offer to branded GLP-1 drugs. The company guides to 2026 adjusted EBITDA of $275 million to $325 million on revenue of $3.1 billion to $3.3 billion.
Last 12 monthsChart & venues →
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Biggest businessesAll products & projects →
Subscription platform (sexual health, hair, dermatology, mental health)
2.891 million subscribers at the end of Q2 2026, up 19 percent year over year.
Weight loss (GLP-1 programs)
US offer moved to branded GLP-1 drugs in Q1 2026. Compounded semaglutide remains available only on a limited scale.
Hormone health (testosterone and menopause)
Menopause and perimenopause specialty launched in October 2025 under the Hers brand. Low-testosterone care was also launched in 2025.
Labs (at-home lab testing)
Comprehensive at-home lab testing was launched in 2025 and feeds into treatment plans.
Latest newsAll news →
Hims & Hers names chief medical officers for the UK and Australia
Hims & Hers named Kultar Garcha, MD, as Chief Medical Officer for the UK and EMEA, and Matt Vickers as Chief Medical Officer of Hims Australia.
Hims & Hers shares slide as costly weight-loss push squeezes margins
Hims & Hers shares fell more than 2% in morning trading after second-quarter results, with investors focused on falling gross margins.
Hims & Hers Q2 2026 revenue up 38% to $753 million, but net loss and margin squeeze
Hims & Hers reported second-quarter 2026 revenue of $753.2 million, up 38%, with 2.891 million subscribers.
Hims & Hers completes Eucalyptus acquisition, adding Australia and more customers
Hims & Hers closed its acquisition of Eucalyptus under the terms of the February agreement.
Hims & Hers prices upsized $350 million 0% convertible notes due 2032
Hims & Hers priced an upsized private offering of $350 million of 0% convertible senior notes due June 1, 2032, up from an original $300 million.
Bank of America cuts Hims & Hers target to $30 from $32, keeps Neutral
Bank of America lowered its price target on Hims & Hers to $30 from $32 and kept a Neutral rating.
Products & businesses
Subscription platform (sexual health, hair, dermatology, mental health)
2.891 million subscribers at the end of Q2 2026, up 19 percent year over year.
Weight loss (GLP-1 programs)
US offer moved to branded GLP-1 drugs in Q1 2026. Compounded semaglutide remains available only on a limited scale.
Hormone health (testosterone and menopause)
Menopause and perimenopause specialty launched in October 2025 under the Hers brand. Low-testosterone care was also launched in 2025.
Labs (at-home lab testing)
Comprehensive at-home lab testing was launched in 2025 and feeds into treatment plans.
International (Zava and other markets)
Rest of World revenue reached $131.4 million in Q2 2026, up from $7.5 million a year earlier, helped by the Eucalyptus deal closing in June.
Eucalyptus (Australia and digital health brands)
Closed on June 2, 2026. The company says Eucalyptus has served more than 850,000 customers.
What it's building next
Segments
| Segment | Revenue | Share | |
|---|---|---|---|
| United States Subscription revenue from US customers across sexual health, hair, dermatology, mental health, weight loss, hormone health and lab testing. | $2.21B | 94.3% | |
| Rest of World Revenue from outside the US, starting with the UK and Europe through Zava, which the company bought in 2025. | $134.0M | 5.7% |
Fiscal 2025 · from the annual report
Valuation & fundamentals
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price.
Financial statements
| Metric | TTM | Q2 FY2026 2026-06-30 | Q1 FY2026 2026-03-31 | Q4 FY2025 2025-12-31 | Q3 FY2025 2025-09-30 | Q2 FY2025 2025-06-30 | Q1 FY2025 2025-03-31 | Q4 FY2024 2024-12-31 | Q3 FY2024 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $753.2M +38% | $608.1M +4% | $617.8Md +28% | $599.0M +49% | $544.8M +73% | $586.0M +111% | $481.1Md +95% | $401.6M +77% |
| Gross profit | $1.76B | $480.8M +16% | $396.8M -8% | $444.4Md +20% | $442.1M +39% | $416.2M +62% | $430.7M +88% | $369.5Md +81% | $317.9M +70% |
| Operating income | −$154.5M | −$97.2M -464% | −$78.3M -235% | $9.2Md -51% | $11.8M -47% | $26.7M +142% | $57.9M +485% | $18.6Md | $22.4M |
| Net income | −$142.0M | −$86.3M -303% | −$92.1M -286% | $20.6Md -21% | $15.8M -79% | $42.5M +220% | $49.5M +345% | $26.0Md +1990% | $75.6M |
| EPS (diluted) | $-0.63 | $-0.37 -318% | $-0.40 -300% | $0.08d -20% | $0.06 -81% | $0.17 +183% | $0.20 +300% | $0.10d +900% | $0.32 |
| Operating cash flow | $263.4M | −$35.9Md | $89.4M -18% | $61.3Md -29% | $148.7Md +74% | −$19.1Md -136% | $109.1M +322% | $86.4Md +293% | $85.3Md +238% |
| Capital expenditure | $201.9M | $32.3M -36% | $36.3M -38% | $63.9Md +138% | $69.4M +1076% | $50.4M +740% | $59.0M +321% | $26.9Md | $5.9M |
| Share buybacks | — | — | — | $80.5Md +1508% | $9.5Md -68% | $0d -100% | $0 -100% | $5.0Md +150% | $30.0Md |
| Cash & equivalents | $609.8M | $609.8M | $222.3M | $228.6M | $345.8M | $1.12B | $273.7M | $220.6M | $165.5M |
| Metric | FY2025 2025-12-31 | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 |
|---|---|---|---|---|
| Revenue | $2.35B +59% | $1.48B +69% | $872.0M +65% | $526.9M |
| Cost of revenue | $614.3M +102% | $303.4M +93% | $157.1M +33% | $118.2M |
| Gross profit | $1.73B +48% | $1.17B +64% | $714.9M +75% | $408.7M |
| Operating income | $105.6M +71% | $61.9M | −$29.5M | −$68.7M |
| EBIT | $105.6M +71% | $61.9M | −$29.5M | −$68.7M |
| Depreciation & amortization | $54.5M +219% | $17.1M +80% | $9.5M +27% | $7.5M |
| Income tax | −$4.4M | −$54.3M -2851% | $2.0M | −$31.0K |
| Net income | $128.4M +2% | $126.0M | −$23.5M | −$65.7M |
| EPS (diluted) | $0.51 -4% | $0.53 | $-0.11 | $-0.32 |
| Diluted shares (weighted) | 258.2M | 236.8M | 209.3M | 204.5M |
| Operating cash flow | $300.0M +19% | $251.1M +242% | $73.5M | −$26.5M |
| Capital expenditure | $242.6M +359% | $52.8M +99% | $26.5M +268% | $7.2M |
| Share buybacks | $90.0M +8% | $83.0M +4054% | $2.0M | $0 |
| Cash & equivalents | $228.6M | $220.6M | $96.7M | $46.8M |
| Total assets | $2.15B | $707.5M | $441.2M | $366.3M |
| Total liabilities | $1.61B | $230.8M | $97.2M | $54.6M |
| Shareholders' equity | $540.9M | $476.7M | $344.0M | $311.7M |
From XBRL data in SEC filings. Small figures under each value: change vs the same period a year earlier. d = derived (e.g. Q4 = full year − first nine months).
NewsFull archive →
Hims & Hers names chief medical officers for the UK and Australia
Hims & Hers named Kultar Garcha, MD, as Chief Medical Officer for the UK and EMEA, and Matt Vickers as Chief Medical Officer of Hims Australia.
Hims & Hers shares slide as costly weight-loss push squeezes margins
Hims & Hers shares fell more than 2% in morning trading after second-quarter results, with investors focused on falling gross margins.
Hims & Hers Q2 2026 revenue up 38% to $753 million, but net loss and margin squeeze
Hims & Hers reported second-quarter 2026 revenue of $753.2 million, up 38%, with 2.891 million subscribers.
Hims & Hers completes Eucalyptus acquisition, adding Australia and more customers
Hims & Hers closed its acquisition of Eucalyptus under the terms of the February agreement.
Hims & Hers prices upsized $350 million 0% convertible notes due 2032
Hims & Hers priced an upsized private offering of $350 million of 0% convertible senior notes due June 1, 2032, up from an original $300 million.
Bank of America cuts Hims & Hers target to $30 from $32, keeps Neutral
Bank of America lowered its price target on Hims & Hers to $30 from $32 and kept a Neutral rating.
Hims & Hers Q1 2026 net loss of $92 million; Q2 and full-year guidance set
Hims & Hers reported first-quarter 2026 revenue of $608.1 million, up 4%, and a net loss of $92.1 million, against net income a year earlier.
Hims & Hers nominates Kofi Amoo-Gottfried to its board and shrinks it to nine
Hims & Hers nominated Kofi Amoo-Gottfried, a former chief marketing officer at DoorDash, as a new director for election at its 2026 annual meeting.
Hims & Hers to sell Novo Nordisk's Ozempic and Wegovy and drop compounded GLP-1 ads
Hims & Hers and Novo Nordisk agreed to sell Novo's branded Ozempic and Wegovy, including the Wegovy pill, on the Hims platform.
Hims & Hers guides Q1 2026 revenue below expectations and shares fall
Hims & Hers reported fourth-quarter 2025 revenue of $617.8 million, up 28%, and full-year revenue of $2.35 billion, up 59%.
Hims & Hers agrees to buy Eucalyptus in a deal worth up to $1.15 billion
Hims & Hers signed a definitive agreement to acquire Eucalyptus, an Australian-founded digital health company, for up to $1.15 billion.
Novo Nordisk sues Hims & Hers for patent infringement over compounded semaglutide
Novo Nordisk filed a patent infringement suit against Hims & Hers, alleging that its compounded semaglutide products infringe US Patent 8,129,343.
Hims & Hers drops its compounded copy of Novo's Wegovy pill two days after launch
Hims announced a compounded semaglutide pill on February 5, 2026, priced as a low-cost alternative to Novo Nordisk's Wegovy pill.
Hims & Hers reports fiscal Q3 2025 results: revenue $599.0M, up 49% from a year earlier
Hims & Hers filed a Form 8-K with the SEC on Nov 3, 2025, 4:08 PM ET, reporting an event dated Nov 3, 2025.
SEC filings
| Oct 7, 26 | 8-K | 8-K: Director/Officer Change (Item 5.02) | sec.gov ↗ |
| Oct 2, 26 | 4 | Form 4: Okupe Oluyemi (Chief Financial Officer) — open-market sale 2,000 sh | sec.gov ↗ |
| Oct 2, 26 | 4 | Form 4: Boughton Soleil (Chief Legal Officer) — open-market sale 3,461 sh | sec.gov ↗ |
| Oct 1, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 30, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 23, 26 | 4 | Form 4: Okupe Oluyemi (Chief Financial Officer) — option exercise 14,000 sh, open-market sale 29,277 sh | sec.gov ↗ |
| Sep 22, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 18, 26 | 4 | Form 4: Okupe Oluyemi (Chief Financial Officer) — open-market sale 12,313 sh | sec.gov ↗ |
| Sep 17, 26 | 4 | Form 4: Boughton Soleil (Chief Legal Officer) — open-market sale 6,236 sh | sec.gov ↗ |
| Sep 17, 26 | 4 | Form 4: Chi Michael (Chief Operating Officer) — open-market sale 14,027 sh | sec.gov ↗ |
| Sep 17, 26 | 4 | Form 4: Elshenawy Mohamed (CTO) — open-market sale 7,954 sh | sec.gov ↗ |
| Sep 17, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 16, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 15, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 15, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 3, 26 | 4 | Form 4: Boughton Soleil (Chief Legal Officer) — open-market sale 3,458 sh | sec.gov ↗ |
| Sep 2, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 31, 26 | SCHEDULE 13D/A | SCHEDULE 13D/A: Activist/controlling ownership report (5%+) (amended) | sec.gov ↗ |
| Aug 27, 26 | 4 | Form 4: Dudum Andrew (Chief Executive Officer, Director, 10% Owner) — gift 463,289 sh, other 977,566 sh | sec.gov ↗ |
| Aug 20, 26 | 4 | Form 4: Autor Deborah M. (Chief Policy Officer, Director) — open-market sale 16,773 sh | sec.gov ↗ |
| Aug 20, 26 | 4 | Form 4: Okupe Oluyemi (Chief Financial Officer) — option exercise 4,938 sh, open-market sale 4,938 sh | sec.gov ↗ |
| Aug 20, 26 | 4 | Form 4: Boughton Soleil (Chief Legal Officer) — open-market sale 25,111 sh | sec.gov ↗ |
| Aug 19, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Boughton Soleil (Chief Legal Officer) — option exercise 42,261 sh, tax withholding 21,500 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Schultz Kare (Director) — option exercise 6,623 sh | sec.gov ↗ |
Insider trades, 12 months
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 2.0K | $29.70 | $59.4K |
| 2026-09-30 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 3.5K | $29.17 | $101.0K |
| 2026-09-22 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 29.3K | $29.95 | $876.8K |
| 2026-09-17 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 12.3K | $28.82 | $354.9K |
| 2026-09-16 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 6.2K | $27.86 | $173.7K |
| 2026-09-15 | Elshenawy Mohamed CTO | Sale 10b5-1 plan | 8.0K | $28.39 | $225.8K |
| 2026-09-15 | Chi Michael Chief Operating Officer | Sale 10b5-1 plan | 14.0K | $28.39 | $398.2K |
| 2026-09-02 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 3.5K | $28.33 | $98.0K |
| 2026-08-19 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 25.1K | $27.55 | $691.8K |
| 2026-08-19 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 4.9K | $29.99 | $148.1K |
| 2026-08-18 | Autor Deborah M. Chief Policy Officer, Director | Sale 10b5-1 plan | 16.8K | $27.85 | $467.1K |
| 2026-08-17 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 9.4K | $27.89 | $261.8K |
| 2026-07-17 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 7.2K | $31.99 | $229.2K |
| 2026-07-06 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 7.2K | $36.49 | $261.4K |
| 2026-06-22 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 18.2K | $34.03 | $619.2K |
| 2026-06-18 | Carroll Patrick Harrison Chief Medical Officer | Sale 10b5-1 plan | 23.7K | $35.00 | $830.4K |
| 2026-06-18 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 55.4K | $35.09 | $1.9M |
| 2026-06-17 | Elshenawy Mohamed CTO | Sale 10b5-1 plan | 30.0K | $31.50 | $946.3K |
| 2026-06-17 | Becklund Irene PAO | Sale 10b5-1 plan | 4.5K | $31.50 | $141.4K |
| 2026-06-17 | Chi Michael Chief Operating Officer | Sale 10b5-1 plan | 14.0K | $31.50 | $441.9K |
| 2026-06-16 | Becklund Irene PAO | Sale 10b5-1 plan | 7.6K | $30.25 | $229.1K |
| 2026-05-26 | WELLS DAVID B Director | Buy | 48.4K | $24.23 | $1.2M |
| 2026-05-18 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 8.0K | $23.64 | $187.9K |
| 2026-04-20 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 19.6K | $29.96 | $588.6K |
| 2026-04-20 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 9.5K | $30.00 | $283.9K |